JingXuan Yan, Peng Zhao, Yuanyuan Li, Jing Wang, Xia Yang, Hongbo Li, Liangang Zhuo, Wei Liao, Wenqi Fan, Yaodan Jia, Hongyuan Wei, Yue Chen
BACKGROUND: The radionuclide-labeled bevacizumab (BV) is a potential therapeutic approach for vascular endothelial growth factor overexpressed tumors. Because of its large molecular weight, BV is cleared slowly in vivo, which caused damage to healthy tissues and organs. On account of this situation, using the pretargeting strategy with DNA/RNA analogs, such as peptide nucleic acid (PNA), is an effective way of treating solid tumors. METHODS: The BV-PNA conjugate (BV-PNA-1) was injected intravenously as the pretargeted probe, which was specifically accumulated in a solid tumor and gradually metabolically cleared...
July 16, 2024: Nuclear Medicine Communications